Search

Your search keyword '"Perol, M."' showing total 498 results
Start Over Author "Perol, M."
498 results on '"Perol, M."'

201. Actinomycose bronchique pseudo-tumorale simulant une ré-évolution d’un cancer bronchique 14ans après la prise en charge thérapeutique initiale : à propos d’un cas

Author

Folliet, L., primary, Perpoint, T., additional, Pignat, J.-C., additional, Laurent, F., additional, Devouassoux, M., additional, Perol, M., additional, Nesme, P., additional, Guerin, J.-C., additional, Ernesto, S., additional, Odier, L., additional, and Arpin, D., additional

Published
2015
Full Text
View/download PDF

209. Efficacité du bévacizumab associé à un doublet de chimiothérapie à base de sels de platine en première ligne de traitement des cancers du poumon ALK-réarrangés : analyse des données de l’étude IFCT-1302 CLINALK

Author

Duruisseaux, M., Besse, B., Cadranel, J., Pérol, M., Mennecier, B., Bigay-Game, L., Descourt, R., Dansin, E., Audigier-Valette, C., Moreau, L., Hureaux, J., Veillon, R., Otto, J., Madroszyk-Flandin, A., Cortot, A., Guichard, F., Boudou-Rouquette, P., Langlais, A., Missy, P., Morin, F., and Moro-Sibilot, D.

Published
2017
Full Text
View/download PDF

210. Expression of class III beta tubulin in non-small cell lung cancer is correlated with resistance to taxane chemotherapy

Author

Charles Dumontet, Isaac, S., Souquet, P. J., Bejui-Thivolet, F., Pacheco, Y., Peloux, N., Frankfurter, A., Luduena, R., Perol, M., Institut National de la Santé et de la Recherche Médicale (INSERM), Hospices Civils de Lyon (HCL), Rétrovirus et Pathologie Comparée (RPC), Institut National de la Recherche Agronomique (INRA)-École pratique des hautes études (EPHE), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Ecole Nationale Vétérinaire de Lyon (ENVL), University of Virginia, University of Texas Health Science Center, The University of Texas Health Science Center at Houston (UTHealth), and ProdInra, Migration

Subjects
[SDV] Life Sciences [q-bio], NON-SMALL CELL LUNG, BETA TUBULIN, [SDV]Life Sciences [q-bio], CHEMOTHERAPY, TAXANE, RESISTANCE
Abstract

International audience; This study determined the prevalence and the prognostic value of the expression of microtubule components in tumors of 19 patients with non small cell lung cancer receiving taxane-based regimens. Patient samples were stained with antibodies directed against total β tubulin, classes I, II and III β tubulin isotypes, δ2 alpha tubulin, τ protein, and the P-gp protein involved in the classical multidrug resistance phenotype. All tumors were stained with pan-β tubulin antibody and class I tubulin isotype. A majority of the tumor samples expressed class II and class III, although the percentage of positive cells varied significantly between tumors. δ2 alpha tubulin, τ protein and Pgp protein were found in only one tumor sample each. Progression-free survival was shorter (41 days) in patients whose tumors expressed high levels of class III tubulin isotype in comparison to patients with low levels (288 days, p = 0.02). There were 2 responses to chemotherapy among 9 patients (22%) with high levels of class III tubulin vs. 6 among 10 patients (60%) with low levels of expression (Fisher exact test: p = 0.11). These data suggest that high expression of class III tubulin by tumor cells is associated with poor prognosis in patients with NSCLC receiving a taxane-based regimen.

Published
2005

212. Quality of Life (Qol) Results from the Phase 3 Revel Study of Ramucirumab + Docetaxel (Ram + Dtx) Versus Placebo + Docetaxel (Pl + Dtx) in Advanced/Metastatic Nsclc Patients (Pts) with Progression After Platinum Based Chemotherapy

Author

Garon, E.B., primary, Ciuleanu, T., additional, Arrieta, O., additional, Prabhash, K., additional, Syrigos, K.N., additional, Göksel, T., additional, Park, K., additional, Kowalyszyn, R., additional, Pikiel, J., additional, Lewanski, C., additional, Thomas, M., additional, Dakhil, S., additional, Kim, J., additional, Karaseva, N., additional, Yurasov, S., additional, Zimmermann, A., additional, Carter, G. Cuyun, additional, Reck, M., additional, Cappuzzo, F., additional, and Perol, M., additional

Published
2014
Full Text
View/download PDF

213. Retrospective Multicenter Study in Non Small Cell Lung Cancer (Nsclc) Patients with Epidermal Growth Factor Receptor (Egfr) Activating Mutation Treated First-Line Tyrosine Kinase Inhibitor (Tki): Evaluation of Progression According to Recist, Therapeutic Approach and Its Effect

Author

Auliac, J.B., primary, Fournier, C., additional, Valette, C. Audigier, additional, Perol, M., additional, Bizieux, A., additional, Monnet, I., additional, De van Ho, C. croisette Phan, additional, Ouchlif, S. Bota, additional, Corre, R., additional, Garff, G. Le, additional, Fournel, P., additional, Baize, N., additional, Lamy, R., additional, Vergnenegre, A., additional, Arpin, D., additional, Marin, B., additional, Greillier, L., additional, and Gervais, R., additional

Published
2014
Full Text
View/download PDF

216. Chimiothérapie (CT) de maintenance par bevacizumab/pemetrexed chez des patients (pts) avec un cancer bronchique non à petites cellules non épidermoïdes (CBNPCne) avancé : survie globale actualisée de l’essai randomisé de phase III AVAPERL

Author

Barlesi, F., primary, Gervais, R., additional, Chouaid, C., additional, Souquet, P.J., additional, Milleron, B., additional, Monnet, I., additional, Étienne-Mastroiani, B., additional, Berard, H., additional, Deplanque, G., additional, Zalcman, G., additional, Domas, J., additional, Pichon, E., additional, Janicot, H., additional, Perol, M., additional, Shott, R., additional, Vaylet, F., additional, Genet, D., additional, Moro-Sibilot, D., additional, Fournel, P., additional, Falchero, L., additional, Morando, C., additional, Loundou, A., additional, and Scherpereel, A., additional

Published
2014
Full Text
View/download PDF

218. Psoriasis induits par les chimiothérapies anti-PD1

Author

Bonigen, J., Raynaud-Donzel, C., Hureaux, J., Kramkimel, N., Blom, A., Jeudy, G., Breton, A.-L., Hubiche, T., Bedane, C., Legoupil, D., Pham-Ledard, A., Pérol, M., Gérard, E., Combemale, P., Bonnet, D., Sigal, M.-L., and Mahé, E.

Published
2016
Full Text
View/download PDF

220. 1296TiP - A phase 2 study of seribantumab (MM-121) in combination with docetaxel or pemetrexed versus docetaxel or pemetrexed alone in patients with heregulin positive (HRG+), locally advanced or metastatic non-small cell lung cancer (NSCLC)

Author

Sequist, L.V., Anderson, I., Bauer, T.M., Demars, N., Felip, E., Frost, N., Harb, W., Horn, L., Huber, R.M., Kudla, A.J., Lee, J., Mathews, S., Mehra, R., Nieva, J., Perol, M., Shepherd, F., Spira, A., and Czibere, A.

Published
2016
Full Text
View/download PDF

224. Efficacité du pemetrexed en 2e ligne dans les CBNPC avancé après un intervalle libre ou un traitement de maintenance par gemcitabine ou erlotinib dans l’étude IFCT-GFPC 05-02

Author

Bylicki, O., primary, Segura, C., additional, Chouaid, C., additional, Lavolé, A., additional, Barlesi, F., additional, Gervais, R., additional, Westeel, V., additional, Crequit, J., additional, Corre, R., additional, Vergnenègre, A., additional, Zalcman, G., additional, Monnet, I., additional, Le Caer, H., additional, Fournel, P., additional, Linard, P., additional, Perol, D., additional, and Perol, M., additional

Published
2013
Full Text
View/download PDF

227. Cost-Utility Analysis of Maintenance Therapy with Either Gemcitabine or Erlotinib versus Observation with Predefined Second-Line Treatment after Cisplatin-Gemcitabine Induction Chemotherapy in Advanced Nsclc: Ifct-Gfpc 0502-ECO Phase III Study

Author

Borget, I., primary, Perol, M., additional, Perol, D., additional, Lavole, A., additional, Greillier, L., additional, Gervais, R., additional, Zalcman, G., additional, Chabaud, S., additional, Vergnenegre, A., additional, and Chouaid, C., additional

Published
2012
Full Text
View/download PDF

230. Maintenance with either gemcitabine or erlotinib versus observation with predefined second-line treatment after cisplatin-gemcitabine induction chemotherapy in advanced NSCLC: IFCT-GFPC 0502 phase III study.

Author

Perol, M., primary, Chouaid, C., additional, Milleron, B. J., additional, Gervais, R., additional, Barlesi, F., additional, Westeel, V., additional, Crequit, J., additional, Lena, H., additional, Vergnenegre, A., additional, and Pérol, D., additional

Published
2010
Full Text
View/download PDF

234. Comment traiter la rechute du CBNPC après une chirurgie et chimiothérapie ?

Author

Moro-Sibilot, D., primary, Barlesi, F., additional, Timsit, J.F., additional, Debieuvre, D., additional, Fournel, P., additional, Gervais, R., additional, Mazieres, J., additional, Milleron, B., additional, Morin, F., additional, Perol, M., additional, Soria, J.C., additional, Souquet, P.J., additional, Vergnenègre, A., additional, and Zalcman, G., additional

Published
2008
Full Text
View/download PDF

235. An open multicenter phase II trial of docetaxel–gemcitabine in Charlson score and performance status (PS) selected elderly patients with stage IIIB pleura/IV non-small-cell lung cancer (NSCLC): The GFPC 02-02a study

Author

LeCaer, H., primary, Fournel, P., additional, Jullian, H., additional, Chouaid, C., additional, LeTreut, J., additional, Thomas, P., additional, Paillotin, D., additional, Perol, M., additional, Gimenez, C., additional, and Vergnenegre, A., additional

Published
2007
Full Text
View/download PDF

236. IFCT0401-bio trial: Predictive biological markers for disease control (DC) of patients with non-resectable, adenocarcinoma with bronchioloalveolar carcinoma features (ADC-BAC) treated with gefitinib

Author

Wislez, M., primary, Antoine, M., additional, Poulot, V., additional, Morere, J. F., additional, Perol, M., additional, Souquet, P. J., additional, Lebitasy, M. P., additional, Zalcman, G., additional, Coulet, F., additional, and Cadranel, J., additional

Published
2007
Full Text
View/download PDF

239. Evaluation of RECIST in chemotherapy-treated lung cancer: the Pharmacogenoscan Study.

Author

Toffart, A. C., Moro-Sibilot, D., Couraud, S., Merle, P., Perol, M., Girard, N., Souquet, P. J., Mastroianni, B., Ferretti, G. R., Romand, P., Chatellain, P., Vesin, A., Brambilla, E., Brambilla, C., and Timsit, J. F.

Subjects
LUNG cancer treatment, CANCER patients, CANCER chemotherapy, PHARMACOGENOMICS, CANCER invasiveness, MEDICAL databases, SURVIVAL analysis (Biometry)
Abstract

Background Response Evaluation Criteria in Solid Tumors (RECIST) are widely used to assess the effect of chemotherapy in patients with cancer. We hypothesised that the change in unidimensional tumour size handled as a continuous variable was more reliable than RECIST in predicting overall survival (OS). Methods The prospective Pharmacogenoscan study enrolled consecutive patients with non-small-cell lung cancer (NSCLC) at any stage seen between 2005 and 2010 at six hospitals in France, given chemotherapy. After exclusion of patients without RECIST or continuous-scale tumour size data and of those with early death, 464 patients were left for the survival analyses. Cox models were built to assess relationships between RECIST 1.1 categories or change in continuous-scale tumour size and OS. The best model was defined as the model minimising the Akaike Information Criterion (AIC). Results OS was 14.2 months (IQR, 7.3-28.9 months). According to RECIST 1.1, 146 (31%) patients had a partial or complete response, 245 (53%) stable disease, and 73 (16%) disease progression. RECIST 1.1 predicted better OS than continuous-scale tumour in early (<6 months) predicted survival analyses (p = 0.03) but the accuracy of the two response evaluation methods was similar in late (≤6 months) predicted survival analyses (p = 0.15). Conclusion In this large observational study, change in continuous-scale tumour size did not perform better than RECIST 1.1 in predicting survival of patients given chemotherapy to treat NSCLC. [ABSTRACT FROM AUTHOR]

Published
2014
Full Text
View/download PDF

241. IFCT0401-bio trial: Pathological and EGF-r molecular analysis of tumor-biopsy samples from patients with non-resectable, pneumonic-type adenocarcinoma (P-ADC) treated by gefinitib. Preliminary results from surgical specimens

Author

Cadranel, J., primary, Wislez, M., additional, Coulet, F., additional, Poulot, V., additional, Morã, J. F., additional, Debove, P., additional, Perol, M., additional, Souquet, P. J., additional, Soubrier, F., additional, and Antoine, M., additional

Published
2006
Full Text
View/download PDF

243. PCN61 - Economic Impact of Centralized Histological Reviews in Patients with Sarcoma, Gist, and Desmoid Tumors

Author

Perrier, L., Kembou, Nzale S., Rascle, P., Bui, B., Morelle, M., Ranchère, Vince D., Terrier, P., Neuville, A., Decouvelaere, A.V., Le Cesne, A., Gomez, F., de la Fouchardière, C., Meeus, P., Trédan, O., Pérol, M., Fayette, J., Neidhardt, E.M., Biron, P., Boyle, H.J., Marec, Bérard P., Farsi, F., Ducimetière, F., Blay, J.Y., Ray, Coquard I., and Coindre, J.M.

Published
2014
Full Text
View/download PDF

250. Summary of the Standards, Options and Recommendations for the management of patients with carcinoma of unknown primary site (2002)

Author

Bugat, R, primary, Bataillard, A, additional, Lesimple, T, additional, Voigt, J J, additional, Culine, S, additional, Lortholary, A, additional, Merrouche, Y, additional, Ganem, G, additional, Kaminsky, M C, additional, Negrier, S, additional, Perol, M, additional, Laforêt, C, additional, Bedossa, P, additional, Bertrand, G, additional, Coindre, J M, additional, and Fizazi, K, additional

Published
2003
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results